

# Fabio Fimiani

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2297474/publications.pdf>

Version: 2024-02-01

38  
papers

1,336  
citations

394421

19  
h-index

345221

36  
g-index

39  
all docs

39  
docs citations

39  
times ranked

2368  
citing authors

#	ARTICLE	IF	CITATIONS
1	Inflammation and Cardiovascular Disease: From Pathogenesis to Therapeutic Target. <i>Current Atherosclerosis Reports</i> , 2014, 16, 435.	4.8	413
2	The Role of von Willebrand Factor in Vascular Inflammation: From Pathogenesis to Targeted Therapy. <i>Mediators of Inflammation</i> , 2017, 2017, 1-13.	3.0	173
3	Lipoprotein(a): a genetic marker for cardiovascular disease and target for emerging therapies. <i>Journal of Cardiovascular Medicine</i> , 2021, 22, 151-161.	1.5	53
4	Beyond cholesterol metabolism: The pleiotropic effects of proprotein convertase subtilisin/kexin type 9 (PCSK9). Genetics, mutations, expression, and perspective for long-term inhibition. <i>BioFactors</i> , 2020, 46, 367-380.	5.4	46
5	Hypertrophic Cardiomyopathy in Children: Pathophysiology, Diagnosis, and Treatment of Non-sarcomeric Causes. <i>Frontiers in Pediatrics</i> , 2021, 9, 632293.	1.9	43
6	Adipose tissue and vascular inflammation in coronary artery disease. <i>World Journal of Cardiology</i> , 2014, 6, 539.	1.5	42
7	Impact of PCSK9 inhibitors on the quality of life of patients at high cardiovascular risk. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 556-558.	1.8	39
8	Molecular Basis of Inflammation in the Pathogenesis of Cardiomyopathies. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6462.	4.1	38
9	Impact of lipoprotein(a) levels on recurrent cardiovascular events in patients with premature coronary artery disease. <i>Internal and Emergency Medicine</i> , 2019, 14, 621-625.	2.0	37
10	Prevalence and clinical implications of eligibility criteria for prolonged dual antithrombotic therapy in patients with PEGASUS and COMPASS phenotypes: Insights from the START-ANTIPLATELET registry. <i>International Journal of Cardiology</i> , 2021, 345, 7-13.	1.7	35
11	Adherence to proprotein convertase subtilisin/kexin 9 inhibitors in high cardiovascular risk patients. <i>Journal of Cardiovascular Medicine</i> , 2018, 19, 75-77.	1.5	34
12	Exercise, Immune System, Nutrition, Respiratory and Cardiovascular Diseases during COVID-19: A Complex Combination. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 904.	2.6	32
13	Low-Dose Ticagrelor in Patients With High Ischemic Risk and Previous Myocardial Infarction: A Multicenter Prospective Real-World Observational Study. <i>Journal of Cardiovascular Pharmacology</i> , 2020, 76, 173-180.	1.9	31
14	Von Willebrand Factor and Cardiovascular Disease: From a Biochemical Marker to an Attractive Therapeutic Target. <i>Current Vascular Pharmacology</i> , 2017, 15, 404-415.	1.7	28
15	The Biological Role of Vitamins in Athletes' Muscle, Heart and Microbiota. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 1249.	2.6	27
16	Laboratory medicine: health evaluation in elite athletes. <i>Clinical Chemistry and Laboratory Medicine</i> , 2019, 57, 1450-1473.	2.3	25
17	Dietary Thiols: A Potential Supporting Strategy against Oxidative Stress in Heart Failure and Muscular Damage during Sports Activity. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 9424.	2.6	23
18	Efficacy and safety of lomitapide in homozygous familial hypercholesterolaemia: the pan-European retrospective observational study. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 832-841.	1.8	23

#	ARTICLE	IF	CITATIONS
19	From Femoral to Radial Approach in Coronary Intervention. <i>Angiology</i> , 2017, 68, 281-287.	1.8	21
20	Effect of Body Mass Index on Ischemic and Bleeding Events in Patients Presenting With Acute Coronary Syndromes (from the START-ANTIPLATELET Registry). <i>American Journal of Cardiology</i> , 2019, 124, 1662-1668.	1.6	20
21	The Risk of Sudden Unexpected Cardiac Death in Children. <i>Heart Failure Clinics</i> , 2022, 18, 115-123.	2.1	16
22	New Frontiers in the Treatment of Homozygous Familial Hypercholesterolemia. <i>Heart Failure Clinics</i> , 2021, 18, 177-188.	2.1	14
23	Lomitapide in homozygous familial hypercholesterolemia: cardiology perspective from a single-center experience. <i>Journal of Cardiovascular Medicine</i> , 2018, 19, 83-90.	1.5	13
24	Diagnostic issues faced by a rare disease healthcare network during Covid-19 outbreak: data from the Campania Rare Disease Registry. <i>Journal of Public Health</i> , 2022, 44, 586-594.	1.8	12
25	Long-term efficacy of lipoprotein apheresis and lomitapide in the treatment of homozygous familial hypercholesterolemia (HoFH): a cross-national retrospective survey. <i>Orphanet Journal of Rare Diseases</i> , 2021, 16, 381.	2.7	12
26	Diagnosis and Management of Cardiovascular Involvement in Friedreich Ataxia. <i>Heart Failure Clinics</i> , 2022, 18, 31-37.	2.1	12
27	Childhood obesity: an overview of laboratory medicine, exercise and microbiome. <i>Clinical Chemistry and Laboratory Medicine</i> , 2020, 58, 1385-1406.	2.3	11
28	Multidisciplinary In-Depth Investigation in a Young Athlete Suffering from Syncope Caused by Myocardial Bridge. <i>Diagnostics</i> , 2021, 11, 2144.	2.6	11
29	Can apical ballooning cardiomyopathy and anterior STEMI be differentiated based on $\beta_1$ and $\beta_2$ -adrenergic receptors polymorphisms?. <i>International Journal of Cardiology</i> , 2015, 199, 189-192.	1.7	10
30	Von Willebrand Factor as a Novel Player in Valvular Heart Disease: From Bench to Valve Replacement. <i>Angiology</i> , 2018, 69, 103-112.	1.8	8
31	Methicillin-Resistant <i>Staphylococcus aureus</i> : Risk for General Infection and Endocarditis Among Athletes. <i>Antibiotics</i> , 2020, 9, 332.	3.7	8
32	Improving Adherence to Ticagrelor in Patients After Acute Coronary Syndrome: Results from the PROGRESS Trial. <i>Current Vascular Pharmacology</i> , 2020, 18, 294-301.	1.7	8
33	ECG analysis in patients with acute coronary syndrome undergoing invasive management: rationale and design of the electrocardiography sub-study of the MATRIX trial. <i>Journal of Electrocardiology</i> , 2019, 57, 44-54.	0.9	7
34	Coronary Physiology Assessment for the Diagnosis and Treatment of Coronary Artery Disease. <i>Cardiology Clinics</i> , 2020, 38, 575-588.	2.2	5
35	Lomitapide does not alter PCSK9 and Lp(a) levels in homozygous familial hypercholesterolemia patients: Analysis on cytokines and lipid profile. <i>Atherosclerosis Plus</i> , 2021, 43, 7-9.	0.7	5
36	MicroRNAs: From Junk RNA to Life Regulators and Their Role in Cardiovascular Disease. <i>Neurology International</i> , 2021, 11, 230-254.	0.5	1

#	ARTICLE	IF	CITATIONS
37	760 Prevalence of eligibility criteria for prolonged dual antithrombotic therapy in patients with PEGASUS and COMPASS phenotypes: insights from the start-antiplatelet registry. European Heart Journal Supplements, 2021, 23, .	0.1	0
38	785 SGLT2 inhibitors in real-life patients at high cardiovascular risk. European Heart Journal Supplements, 2021, 23, .	0.1	0